Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

The prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.

Methods

We retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.

Results

Six randomized controlled trials (RCTs) of bevacizumab combined

SUBMITTER: Song L 

PROVIDER: S-EPMC10289163 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature